ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2020-02-12 09:27 (2312 d 06:08 ago) – Posting: # 21162
Views: 13,149

Hi MS,

Art.75. For two-stage studies, the following should be noted: It is acceptable to use a two-stage approach to demonstrate bioequivalence based on ignorance of the intra-individual variability of the drug;



Ermmm...... WHAT???? :-D:party:

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
178 visitors (0 registered, 178 guests [including 11 identified bots]).
Forum time: 16:36 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5